Teen and young women with systemic lupus erythematosus (SLE) have a higher risk of adverse pregnancy-related outcomes, including hypertensive disorders, maternal death, preterm birth, spontaneous abortion, and induced abortion, according to researchers. Their study, “Adverse pregnancy outcomes in adolescents and young women with systemic lupus erythematosus: a…
Top-line results of ImmuPharma’s Phase 3 clinical trial testing Lupuzor (rigerimod) as a systemic lupus erythematosus (SLE) treatment are expected by mid-April, according to the company. ImmuPharma also announced that database lock of the trial is expected by April 6. This milestone prevents unauthorized or unintended alterations to…
Suppressing the key inflammatory protein iRhom2 reduced inflammation and prevented kidney scarring in mice susceptible to developing lupus, a study suggests. This approach could be the basis of new treatments for kidney damage in patients with lupus and other autoimmune diseases, researchers believe. The study, “iRhom2 promotes…
New York scientists have come up with a new way to measure electric signals in the major nerve running from the head to the abdomen — a discovery that could improve diagnosis and treatment of inflammatory diseases like lupus. The team at the Feinstein Institute for Medical Research used mice to do…
It took more than three years for 1,000 Britons with lupus, scleroderma and vasculitis to obtain a correct diagnosis after their symptoms began, a study shows. The research was based on a survey of 2,000 patients’ shared experiences, so the three-year delayed affected about half. The Rare Autoimmune Rheumatic…
Lupus patients’ risk of an autoimmune reaction while receiving a cancer immunotherapy is no greater than the general population’s, a Mayo Clinic study reports. The same is true of other rheumatic diseases, most of which affect joints and connective tissue, researchers said. Few people have flare-ups of these disorders when they go on…
Cerebrovascular events are the fourth most frequent neuropsychiatric event in systemic lupus erythematosus (SLE) patients and mostly are due to SLE rather than other causes, a new multi-national study shows. Stroke and transient ischemia were the most common cerebrovascular events in these patients. The research, “Cerebrovascular Events in…
The Phase 1b trial testing RA101495 as a treatment for patients with renal impairment diseases, including lupus nephritis, has dosed its first participants, according to Ra Pharmaceuticals. The multi-center trial will determine the pharmacokinetics (how the body metabolizes, distributes, and excretes a drug) of subcutaneous RA101495 in these patients. RA101495…
The PRKCB gene is significantly more expressed in lupus patients than in healthy controls, a new Chinese study shows. But the gene appears to have a protective role, as patients with higher PRKCB expression have lower disease activity scores. The research, “Increased expression of PRKCB mRNA in peripheral blood mononuclear…
Corbus Pharmaceuticals recently started a Phase 2 clinical trial evaluating anabasum as an investigational therapy for the treatment of systemic lupus erythematosus (SLE). Anabasum is a synthetic endocannabinoid mimetic drug, meaning it mimics the action of endocannabinoids, which are endogenous molecules that bind to cannabinoid receptors in the nervous system. The drug…